A detailed history of Schroder Investment Management Group transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Schroder Investment Management Group holds 32,299 shares of BGNE stock, worth $6.27 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
32,299
Previous 84,288 61.68%
Holding current value
$6.27 Million
Previous $12 Million 39.7%
% of portfolio
0.01%
Previous 0.01%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$143.93 - $224.51 $7.48 Million - $11.7 Million
-51,989 Reduced 61.68%
32,299 $7.25 Million
Q2 2024

Aug 12, 2024

BUY
$129.52 - $174.32 $1.35 Million - $1.82 Million
10,427 Added 14.12%
84,288 $12 Million
Q1 2024

May 14, 2024

BUY
$141.8 - $181.47 $8.67 Million - $11.1 Million
61,161 Added 481.58%
73,861 $11.6 Million
Q4 2023

Feb 13, 2024

BUY
$158.67 - $201.58 $2.02 Million - $2.56 Million
12,700 New
12,700 $2.29 Million
Q1 2022

May 16, 2022

SELL
$146.52 - $269.56 $39,999 - $73,589
-273 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$248.56 - $389.34 $68,602 - $107,457
-276 Reduced 50.27%
273 $6,000
Q3 2021

Nov 12, 2021

BUY
$249.6 - $403.14 $126,547 - $204,391
507 Added 1207.14%
549 $15,000
Q2 2021

Aug 13, 2021

SELL
$292.75 - $367.01 $877,371 - $1.1 Million
-2,997 Reduced 98.62%
42 $14,000
Q1 2021

May 17, 2021

BUY
$260.64 - $382.12 $792,084 - $1.16 Million
3,039 New
3,039 $1.06 Million
Q4 2020

Feb 16, 2021

SELL
$221.31 - $316.61 $32,089 - $45,908
-145 Closed
0 $0
Q3 2020

Nov 13, 2020

BUY
$189.18 - $286.44 $27,431 - $41,533
145 New
145 $41,000
Q2 2020

Aug 13, 2020

SELL
$123.9 - $195.41 $10,283 - $16,219
-83 Closed
0 $0
Q1 2020

May 15, 2020

BUY
$121.84 - $173.19 $10,112 - $14,374
83 New
83 $12,000
Q2 2018

Aug 13, 2018

SELL
$152.5 - $216.77 $427,000 - $606,956
-2,800 Closed
0 $0
Q1 2018

May 11, 2018

BUY
$97.41 - $177.22 $272,748 - $496,216
2,800 New
2,800 $470,000

Others Institutions Holding BGNE

About BeiGene, Ltd.


  • Ticker BGNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,700,000
  • Market Cap $20.1B
  • Description
  • BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...
More about BGNE
Track This Portfolio

Track Schroder Investment Management Group Portfolio

Follow Schroder Investment Management Group and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Schroder Investment Management Group, based on Form 13F filings with the SEC.

News

Stay updated on Schroder Investment Management Group with notifications on news.